{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:31:14Z","timestamp":1768685474213,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/maj.0b013e31821f0552","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T07:14:21Z","timestamp":1310627661000},"page":"46-51","source":"Crossref","is-referenced-by-count":33,"title":["Changes in Urinary Albumin Excretion, Inflammatory and Oxidative Stress Markers in ADPKD Patients with Hypertension"],"prefix":"10.1016","volume":"343","author":[{"given":"Tsukasa","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kawagoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31821f0552_bb0005","first-page":"1173","article-title":"Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107months","volume":"26","author":"De Almeida","year":"2007","journal-title":"Rev Port Cardiol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/08860220601038892","article-title":"Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease","volume":"29","author":"Namli","year":"2007","journal-title":"Ren Fail"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1523-1755.2005.00488.x","article-title":"A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease","volume":"68","author":"Casal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0020","first-page":"619","article-title":"Cytokine profile in autosomal dominant polycystic kidney disease","volume":"41","author":"Merta","year":"1997","journal-title":"Biochem Mol Biol Int"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0025","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1681\/ASN.V134991","article-title":"Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease","volume":"13","author":"Maser","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cca.2006.04.016","article-title":"New high mobility group box 1 assay system","volume":"372","author":"Yamada","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0035","doi-asserted-by":"crossref","first-page":"c194","DOI":"10.1159\/000118942","article-title":"High mobility group box chromosomal protein 1 in patients with renal diseases","volume":"108","author":"Sato","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2119\/2007-00107.Bruchfeld","article-title":"High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD)","volume":"14","author":"Bruchfeld","year":"2008","journal-title":"Mol Med"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0045","first-page":"25","article-title":"Therapeutic interventions for autosomal dominant polycystic kidney disease","volume":"22","author":"Edelstein","year":"2008","journal-title":"Nephrol News Issues"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0050","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000107410","article-title":"Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan","volume":"25","author":"Yilmaz","year":"2007","journal-title":"Blood Purif"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijcard.2007.11.003","article-title":"Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril","volume":"132","author":"Yokoyama","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0070","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/dmrr.473","article-title":"Silent cerebral infarction in patients with type 2 diabetes nephropathy","volume":"21","author":"Nakamura","year":"2005","journal-title":"Effects of antiplatelet drug dilazep dihydrochloride. Diabetes Metab Res Rev"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000045963","article-title":"Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease","volume":"88","author":"Nakamura","year":"2001","journal-title":"Nephron"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0085","first-page":"39","article-title":"Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OHdG) by using ELISA","volume":"107","author":"Saito","year":"2000","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/biof.5520220151","article-title":"Comparison of an oxidative stress biomarker \u201curinary 8-hydroxy-2\u2032-deoxyguanosine,\u201d between smokers and non-smokers","volume":"22","author":"Kanaya","year":"2004","journal-title":"Biofactors"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0095","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1373\/49.9.1535","article-title":"High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2","volume":"49","author":"Yamada","year":"2003","journal-title":"Clin Chem"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000112495","article-title":"Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment","volume":"108","author":"Chang","year":"2008","journal-title":"Nephron Physiol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/TCRM.S1617","article-title":"Development in the management of autosomal dominant polycystic kidney disease","volume":"4","author":"Masoumi","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0115","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000081790","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ndt\/gfm731","article-title":"Renal and cardiac effects of antihypertensive treatment with ramipril vs. metoprolol in autosomal dominant polycystic kidney disease","volume":"23","author":"Zeltner","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00000441-200510000-00002","article-title":"Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease","volume":"330","author":"Nakamura","year":"2005","journal-title":"Am J Med Sci"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/112067210801800116","article-title":"Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients","volume":"18","author":"Dong","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0135","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.metabol.2009.03.019","article-title":"Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy","volume":"58","author":"Nakamura","year":"2009","journal-title":"Metabolism"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0140","first-page":"1195","article-title":"Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy","volume":"20","author":"Nakamura","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0145","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s00134-007-0778-9","article-title":"Urinary biomarker of oxidative stress correlating with outcome in critically septic patients","volume":"33","author":"Cheng","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1523-1755.1998.00778.x","article-title":"Redox regulation of renal DNA synthesis, transforming growth factor-beta 1 and collagen gene expression","volume":"53","author":"Nath","year":"1998","journal-title":"Kidney Int"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0011-5029(05)80007-0","article-title":"Polycystic kidney disease: etiology, pathogenesis, and treatment","volume":"41","author":"Martinez","year":"1995","journal-title":"Dis Mon"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2006.07.019","article-title":"HMGB1, a novel inflammatory cytokine","volume":"375","author":"Yamada","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0165","first-page":"26","article-title":"High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases","volume":"10","author":"Voll","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0170","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1097\/01.CCM.0000287588.69000.97","article-title":"Systemic and local high mobility group box 1 concentrations during severe infection","volume":"35","author":"van Zoelen","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0175","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1165\/rcmb.2007-0330OC","article-title":"The role of high mobility group box1 in pulmonary fibrosis","volume":"39","author":"Hamada","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0180","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/2006-00108.Goldstein","article-title":"Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis","volume":"13","author":"Goldstein","year":"2007","journal-title":"Mol Med"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0185","doi-asserted-by":"crossref","first-page":"F775","DOI":"10.1152\/ajprenal.00370.2003","article-title":"The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease","volume":"287","author":"Loghman-Adham","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0190","first-page":"1","article-title":"Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications","volume":"5","author":"Masoumi","year":"2011","journal-title":"Iran J Kidney Dis"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1291\/hypres.31.1","article-title":"Aegis against stroke and dementia by angiotensin type 1 receptor blockers: new beneficial aspects","volume":"31","author":"Morishita","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0200","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/HJH.0b013e328165d159","article-title":"Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker","volume":"25","author":"Shao","year":"2007","journal-title":"J Hypertens"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2007.09.013","article-title":"Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells","volume":"198","author":"Cianchetti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0210","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/HJH.0b013e3282f56ba5","article-title":"Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?","volume":"26","author":"Benson","year":"2008","journal-title":"J Hypertens"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0215","doi-asserted-by":"crossref","first-page":"F465","DOI":"10.1152\/ajprenal.00460.2010","article-title":"PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"300","author":"Yoshihara","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/SMJ.0b013e3181d80cae","article-title":"Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease","volume":"103","author":"Alisir","year":"2010","journal-title":"South Med J"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(00)70195-8","article-title":"Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"35","author":"Ecder","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0230","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease","volume":"18","author":"van Dijk","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e31821f0552_bb0235","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/0886022X.2010.502277","article-title":"A comparison of the effects of ramipril and losartan on blood pressure control and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"32","author":"Ulusoy","year":"2010","journal-title":"Ren Fail"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915310739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915310739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T01:33:10Z","timestamp":1638063190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915310739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0002962915310739"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31821f0552","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}